Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia has revealed positive clinical results from a Phase II study of its T-cell vaccine targeting house dust mite allergy and met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a major reduction in patients' reactions to house dust mite allergens.
Subscribe to our email newsletter
In the current trial, the patients received four standardised doses of ToleroMune T-cell vaccine over a number of weeks.
During the study, investigators administered a challenge dose of house dust mite allergen to the volunteers’ skin and eyes to assess the impact of the ToleroMune therapy.
The results show that the optimal treatment regimen reduced each of the allergic reactions assessed during the study, achieving a therapeutic effect 32% – 87% greater than placebo.
Circassia is currently conducting a number of ongoing Phase II clinical trials with its therapies for grass (hayfever), cat and ragweed allergies.
Circassia CEO Steve Harris said that these positive clinical results, achieved with the house dust mite allergy treatment, are particularly encouraging as they mirror those from earlier successful studies with our cat and ragweed allergy therapies.
"Our growing clinical database clearly demonstrates the potential of Circassia’s T-cell vaccines to greatly improve allergy treatment, by offering sufferers a convenient and well tolerated alternative to existing immunotherapies, Harris said.
"We have made significant progress in advancing a number of allergy T-cell vaccines into mid- to late-stage development, and we continue to work hard to bring these innovative therapies to market as quickly as possible."